Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
Ovid Therapeutics Announces Initiation of Two Phase 2 Clinical Trials of OV935/TAK-935 for Pediatric Patients with Rare Epilepsies
LaFleur Minerals Closes $1.66 Million Flow-Through Offering to Advance Drilling and PEA-Related Work at its Swanson Gold Deposit
